Triple therapy shows longevity


Patients with early rheumatoid arthritis stick with and tolerate triple DMARD therapy reasonably well in real-life practice, a new Australian study shows. The results also showed that treating to the target of remission or low disease activity is more important than the number of DMARDs continued, said the Queensland researchers led by Professor Ranjeny Thomas. ...


Already a member? Login to keep reading


OR
© 2017 the limbic